Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody

Seminars in Oncology

Volumn 29, Issue 5 SUPPL. 14, 2002, Pages 55-60

  Needle, Michael N ^a  

^a ImClone Systems   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; GEMCITABINE; HYDROCORTISONE; IRINOTECAN; RETINOID;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; ASTHENIA; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEVER; GRANULOCYTOPENIA; HEAD AND NECK CANCER; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; LEUKOPENIA; NAUSEA; NEUTROPENIA; PAIN; PANCREAS CANCER; PRIORITY JOURNAL; RASH; SQUAMOUS CELL CARCINOMA; VOMITING;

EID: 0037010077     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(02)70091-2     Document Type: Conference Paper

References (19)

1. Herbst RS, Shin DM: Monoclonal antibodies to target epidermal growth factor receptor-positive tumors. A new paradigm for cancer therapy. Cancer 94:1593-1611, 2002
2. Baselga J: The EGFR as a target for anticancer therapy-Focus on cetuximab. Eur J Cancer 37:S16-S22, 2001
3. Huang S-M, Bock JM, Harari PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59:1935-1940, 1999
4. 1 arrest in prostatic cancer cell line DU145. Cancer Res 56:3666-3669, 1996
5. Bruns CJ, Harbison MT, Davis DW, et al: Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by angiogenic mechanisms. Clin Cancer Res 6:1936-1948, 2000
6. Raben D, Helfrich B, Chan D, et al: C225 anti-EGFR antibody potentiates radiation (RT) and chemotherapy (CT) cytotoxicity in human non-small cell lung cancer (NSCLC) cells in vitro and in vivo. Proc Am Soc Clin Oncol 20:257a, 2001 (abstr 1026)
7. Baselga J, Pfister D, Cooper MR, et al: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18:904-914, 2000
8. Robert F, Ezekiel MP, Spencer SA, et al: Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19:3234-3243, 2001
9. Saltz L, Meropol NJ, Loehrer PJ, et al: Single agent IMC-C225 (Erbitux) has activity in CPT-11 refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 21:127a, 2002 (abstr 504)
10. ImClone Systems Incorporated. Data on file.
11. Cohen RB, Falcey JW, Paulter VJ, et al: Safety profile of the monoclonal antibody (MoAb) IMC-C225, an anti-epidermal growth factor receptor (EGFr) used in the treatment of EGFr-positive tumors. Proc Am Soc Clin Oncol 19:474a, 2000 (abstr 1862)
12. Busam KJ, Capodieci P, Motzer R, et al: Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144:1169-1176, 2001
13. 1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 12:1397-1403, 1996
14. Saltz L, Rubin M, Hochster H, et al: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 20:3a, 2001 (abstr 7)
15. Camptosar, irinotecan hydrochloride injection: Product labeling, Pharmacia, Peapeck, NJ, April 2000
16. Saltz L, Rubin MS, Hochester HS, et al: Acne-like rash predicts response in patients treated with cetuximab (IMC-C225) plus irinotecan (CPT-11) in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proceedings of the American Association for Cancer Research-European Organization for Research and Treatment of Cancer-National Cancer Institute on Molecular Trials and Cancer Therapeutics, Miami, FL, 2001 (abstr 559)
17. Hong WK, Arquette M, Nabell L, et al: Efficacy and safety of the anti-epidermal growth factor antibody (EGFR) IMC-C225, in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc Am Soc Clin Oncol 20:224a, 2001 (abstr 895)
18. Abbruzzese JL, Rosenberg A, Xiong Q, et al: Phase II study of anti-epidermal growth factor receptor (EGFR) anti-body cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 20:130a, 2001 (abstr 518)
19. Burris III HA, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997